In our study, we did not identify any difference in the incidence of molecular alterations in KRAS, NRAS, BRAF, and other common oncogenic drivers and tumor suppressor genes among patients with advanced CRC with liver metastasis compared to those with non-liver metastasis, suggesting worse treatment response and inferior disease control with systemic therapy may not be related to distinct incidence of molecular alterations. This evidence concerns the gene NRAS and colorectal carcinoma.